CTX Study Results

Mirum Phase 3 results announced

Mirum announces positive results from Phase 3 CTX Study.

“The statistically significant reductions in bile alcohols and cholestanol underscore the potential for Chenodal to have a dramatic and meaningful impact on patients with CTX.”

To read full press release: https://ir.mirumpharma.com/news-events/News/news-details/2023/Mirum-Pharmaceuticals-Announces-Positive-Phase-3-RESTORE-Study-Results-Evaluating-Chenodal-in-Patients-with-Cerebrotendinous-Xanthomatosis/default.aspx?_ga=2.140433082.881625098.1696249832-2002651408.1625676440

Alex - The Leukodystrophy Charity